Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Post Quarterly Sales of $4.84 Billion

Analysts expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post $4.84 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Teva Pharmaceutical Industries’ earnings, with the lowest sales estimate coming in at $4.61 billion and the highest estimate coming in at $5.08 billion. Teva Pharmaceutical Industries reported sales of $5.63 billion in the same quarter last year, which would suggest a negative year over year growth rate of 14%. The company is scheduled to issue its next quarterly earnings results on Thursday, May 10th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $4.84 billion for the current year, with estimates ranging from $18.53 billion to $18.82 billion. For the next year, analysts anticipate that the firm will report sales of $18.13 billion per share, with estimates ranging from $17.63 billion to $18.59 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The business had revenue of $5.46 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the prior year, the company posted $1.38 EPS. The business’s revenue for the quarter was down 15.9% compared to the same quarter last year.

Several research firms have recently weighed in on TEVA. Oppenheimer restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Cantor Fitzgerald set a $18.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, February 8th. Gabelli cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and set a $19.00 price objective on the stock. in a research report on Friday, February 9th. Finally, Leerink Swann lowered their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a research report on Friday, February 9th. Ten research analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $21.26.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of Nova Scotia lifted its position in Teva Pharmaceutical Industries by 8.3% during the 2nd quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after acquiring an additional 528 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Teva Pharmaceutical Industries by 1.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock valued at $3,755,000 after acquiring an additional 3,100 shares during the period. WealthTrust Axiom LLC lifted its position in Teva Pharmaceutical Industries by 29.9% during the 4th quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock valued at $283,000 after acquiring an additional 3,440 shares during the period. Argyle Capital Management Inc. lifted its position in Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Argyle Capital Management Inc. now owns 60,750 shares of the company’s stock valued at $1,151,000 after acquiring an additional 3,598 shares during the period. Finally, Guardian Investment Management lifted its position in Teva Pharmaceutical Industries by 26.9% during the 3rd quarter. Guardian Investment Management now owns 17,700 shares of the company’s stock valued at $311,000 after acquiring an additional 3,750 shares during the period. 51.93% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.52 on Wednesday. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The stock has a market cap of $18,430.00, a P/E ratio of -1.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.59.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Teva Pharmaceutical Industries Ltd (TEVA) Will Post Quarterly Sales of $4.84 Billion” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/14/analysts-anticipate-teva-pharmaceutical-industries-ltd-teva-will-post-quarterly-sales-of-4-84-billion.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply